Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.40 |
| ▸ | CTSL | P07711 | 15/20 | 0.40 |
| ▸ | CTSS | P25774 | 11/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | CTSV | O60911 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762064 | 0.91 | RAB9A (0.38) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4763179 | 0.89 | NPC1 (0.35) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4770541 | 0.87 | NPC1 (0.36) | CTSKNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4825080 | 0.87 | L3MBTL1 (0.39) | NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4825088 | 0.87 | L3MBTL1 (0.39) | NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4768763 | 0.87 | RXFP1 (0.37) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4768759 | 0.87 | RXFP1 (0.37) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4763006 | 0.86 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4761996 | 0.86 | MAPT (0.43) | NPC1RAB9ATP53 | |
| SCHEMBL4761995 | 0.86 | MAPT (0.43) | NPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |